Search

Search Constraints

You searched for: Author/Creator Hamberg, Paul

Search Results

1. A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy. (January 2019)

2. A prospective observational registry evaluating clinical outcomes of Radium‐223 treatment in a nonstudy population. Issue 4 (21st January 2020)

3. A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy‐free approach in HER2‐positive metastatic breast cancer: The HAT study (BOOG 2008‐2003), a Dutch Breast Cancer Research Group trial. Issue 19 (17th June 2016)

5. An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients. Issue 1 (December 2016)

6. Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer. Issue 4 (27th February 2019)

7. AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel. Issue 8 (28th June 2019)

8. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer. (November 2019)

9. CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients. (December 2022)

10. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate‐resistant prostate cancer previously treated with docetaxel. Issue 6 (3rd October 2014)